IVD China this week: Mindray, Dian Diagnostics, Getein Biotech, KingMed Diagnostics and MGI

Mindray Reports Third-Quarter 2023 Financial Results

On October 27th, Mindray Medical released its third quarter report, which showed a revenue of CNY27.30 billion in the first three quarters of this year, a year-on-year increase of 17.20%; The net profit attributable to the parent company was CNY9.83 billion, a year-on-year increase of 21.38%.

Against the backdrop of domestic industry consolidation, thanks to the long-term layout of the international market, Mindray Medical still maintained stable growth in the third quarter: it achieved a revenue of CNY8.83 billion in a single quarter, a year-on-year increase of 11.18%; Realized a net profit attributable to the parent company of CNY3.39 billion, a year-on-year increase of 20.52%.

In addition, Mindray Medical has released a profit distribution plan for the first three quarters, intending to distribute a cash dividend of CNY43 (including tax) per 10 shares to all shareholders. Based on Mindray Medical's total share capital of CNY1.21 billion shares as of September 30 this year, a total of CNY5.21 billion in cash dividends is planned to be distributed.

Dian Diagnostics Reports Third-Quarter 2023 Financial Results

On October 28th, Dian Diagnostics released its performance report for the first three quarters of 2023. Among them, the net profit was CNY531 million, a year-on-year decrease of 78.13%.

From the perspective of revenue and profit, the company achieved operating revenue of CNY10.29 billion this year, a year-on-year decrease of 34.15%, net profit of CNY531 million, a year-on-year decrease of 78.13%, and basic earnings per share of CNY0.85.

From the perspective of assets, during the reporting period, the company's total assets at the end of the period were CNY18.75 billion, and accounts receivable were CNY9.39 billion; In terms of cash flow, the net cash flow generated from operating activities was CNY367 million, and the cash received from selling goods and providing services was CNY11.777 billion.

Getein Biotech Reports Third-Quarter 2023 Financial Results

On October 28th, Getein Biotech released its performance report for the first three quarters of 2023. Among them, the net profit was CNY229 million, a year-on-year decrease of 51.80%.

From the perspective of revenue and profit, the company achieved operating revenue of CNY1.001 billion this year, a year-on-year decrease of 27.32%, net profit of CNY229 million, a year-on-year decrease of 51.80%, and basic earnings per share of CNY0.45.

From the perspective of assets, during the reporting period, the company's total assets at the end of the period were CNY3.77 billion, and accounts receivable were CNY449 million; In terms of cash flow, the net cash flow generated from operating activities was CNY147 million, and the cash received from selling goods and providing services was CNY1.149 billion.

KingMed Diagnostics Reports Third-Quarter 2023 Financial Results

As of September 2023, KingMed Diagnostics' net profit attributable to shareholders of the listed company decreased by 76.47% year-on-year, while the net profit attributable to shareholders of the listed company after deducting non recurring gains and losses decreased by 85.81% year-on-year. The main reason is that due to the reduced demand for testing, the company's revenue for medical diagnostic services decreased significantly in the first three quarters. The operating revenue decreased from CNY1,220,791,300 in the same period last year to CNY63,096,221, a year-on-year decrease of 48.32%, But at the same time, as China's medical order returns to normal, the normal medical needs of patients are gradually released, and the company's revenue from routine medical diagnosis services is returning to normal growth.

MGI Reports Third-Quarter 2023 Financial Results

On October 28th, MGI announced its financial report for the third quarter of 2023, with a revenue of CNY760 million, a year-on-year decrease of 18.15%.

In the first three quarters of 2023, the cumulative revenue was CNY2.24 billion, a year-on-year decrease of 33.01%, of which the main business revenue was CNY2.19 billion; The net profit attributable to shareholders of the listed company was CNY-198 million, a year-on-year decrease of 109.78%; The net profit attributable to shareholders of the listed company after deducting non recurring gains and losses was CNY-243 million, a year-on-year decrease of 162.84%. Basic earnings per share were CNY-0.48, a year-on-year decrease of 108.91%.

In the first three quarters, among the main business sectors, the gene sequencer business sector achieved revenue of CNY1.729 billion, a year-on-year increase of 31.47%. The gene sequencer business segment is divided by product type, with a revenue of CNY670 million from instruments and equipment, a year-on-year increase of 15.63%; The revenue from reagent consumables reached CNY1.026 billion, a year-on-year increase of 42.92%; Other income reached CNY31.8452 million, a year-on-year increase of 89.64%.